Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    113
    ...
ATC Name B/G Ingredients Dosage Form Price
C07AA07 SOTALOL BIOGARAN G Sotalol hydrochloride - 80mg 80mg Tablet, scored 288,926 L.L
D10BA01 CONTRACNE ISOTRETINOINE G Isotretinoin - 40mg 40mg Capsule, soft 3,043,803 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g, Lidocaine (ampoule) - 0.5g Injectable powder for solution+diluent 511,940 L.L
J01RA MEDSPIRAGYL G Metronidazole - 125mg, Spiramycin - 750,000IU Tablet, scored 474,824 L.L
M01AH05 CLINTON G Etoricoxib - 90mg 90mg Tablet, film coated 1,280,682 L.L
N02BE01 ADOL G Paracetamol - 125mg 125mg Suppository 107,507 L.L
N06AX21 DULOXA 30 G Duloxetine HCl - 30mg 30mg Capsule, delayed release 716,716 L.L
S01AE01 FLOXEDOL G Ofloxacin - 3mg/ml 3mg/ml Gel 339,992 L.L
A11CC05 DIBASE G Vitamin D3 - 50000IU/2.5ml 50,000IU/2.5ml Solution 755,239 L.L
B03BA01 JECTIN-12 G Cyanocobalamin - 1000mcg/1ml 1000mcg/1ml Injectable solution 567,102 L.L
B05XA03 0.9% SODIUM CHLORIDE INJECTION USP G Sodium chloride - 0.9% 0.9% Injectable solution 145,946 L.L
C09DA01 LOSANET-H G Losartan potassium - 50mg, Hydrochlorothiazide - 12.5mg Tablet 395,474 L.L
C10AA08 PIVAL G Pitavastatin - 4mg 4mg Tablet 1,265,772 L.L
D10BA01 CURACNE G Isotretinoin - 40mg 40mg Capsule, soft gelatin 3,553,120 L.L
G04CA04 SILODOSINE ARROW G Silodosine - 8mg 8mg Capsule 732,394 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution+diluent 511,940 L.L
J01RA SPIRAGYL G Metronidazole - 125mg, Spiramycin - 750,000IU Tablet, scored 474,824 L.L
L01AX03 TEMOZOLOMIDE ACCORD G Temozolomide - 20mg 20mg Capsule, hard 1,153,017 L.L
M01AH05 CONSORT G Etoricoxib - 90mg 90mg Tablet, film coated 338,648 L.L
N02BE01 ALGIVIC INFANT G Paracetamol - 125mg 125mg Suppository 199,657 L.L
N05AD01 HALOPERIDOL G Haloperidol - 5mg 5mg Tablet 276,448 L.L
N06AX21 LOXYT 30 G Duloxetine HCl - 30mg 30mg Capsule, delayed release 716,716 L.L
S01AE02 NAFLOX G Norfloxacin - 3mg/ml 3mg/ml Drops 370,901 L.L
A11CC05 BIO-D3 25000IU G Vitamin D3 - 25000IU 25000IU Capsule 1,130,108 L.L
B03BA05 COBAL G Mecobalamine - 500mcg/ml 500mcg/ml Injectable solution 1,128,828 L.L
B05XA03 0.9% SODIUM CHLORIDE INJECTION USP G Sodium chloride - 0.9% 0.9% Injectable solution 151,692 L.L
C07AB02 B-BLOK SDK G Metoprolol succinate - 50mg 50mg Tablet, controlled release 295,645 L.L
C09DA01 LOSARTAN/HYDROCHLOROTHIAZIDE ARROW LAB G Losartan potassium - 50mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 470,345 L.L
D10BA01 CURACNE G Isotretinoin - 40mg 40mg Capsule, soft gelatin 3,553,120 L.L
G04CA04 SILODOSINE BIOGARAN G Silodosine - 8mg 8mg Capsule 555,007 L.L
    ...
    113
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025